DVA

Business profile & competitive position

DaVita Inc. operates in the Healthcare sector, specifically the Medical - Care Facilities industry, as one of the largest U.S. providers of kidney dialysis and related laboratory services for patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, the company ran 2,657 outpatient dialysis centers in the United States serving roughly 200,500 patients, plus an international footprint of 585 outpatient centers across 14 countries serving approximately 94,500 patients. The business model is heavily domestic: U.S. dialysis accounted for about 86% of consolidated revenues.

The financial signature of the franchise is mixed. Net margin is 6.0%, which is positive but modest for a large-scale healthcare services operator, implying significant operating leverage, fixed-site costs, and dependence on reimbursement and commercial payor pricing rather than wide pricing power. The more striking figure is return on equity of -123.6%. With a positive net margin, a deeply negative ROE usually points to balance-sheet mechanics rather than operational losses—most commonly a shrunken or negative equity base from heavy share repurchases and debt-funded capital returns. That means ROE is not a clean read on competitive moat here; it is a warning that the company is running with little or negative book equity. The one durable qualitative signal in the data is quality leadership: DaVita has led CMS’s Quality Incentive Program for the 11 most recently reported years and the Five-Star Quality Rating System for 10 years, suggesting operational execution is a core part of how it maintains volume and contracting relationships.

Financial posture

DaVita currently carries an $11.0 billion market capitalization and trades at a P/E of 14.8. The 6.0% net margin sits alongside that valuation, so the stock is neither obviously discounted on earnings nor carrying a clear growth premium. Beta is 0.87, meaning the shares have historically moved somewhat less than the overall market, consistent with a defensive, reimbursement-exposed services business. The current price is $171.8, with the 50-day EMA at $201.54, so the stock is trading well below its medium-term moving average. The RSI reads 23.2, a level typically associated with being technically oversold.

The negative ROE of -123.6% is the most important balance-sheet signal in the profile. Investors relying on traditional equity-based screens should treat it carefully: it does not say the company is unprofitable—net margin is positive—but it does say the denominator of the ROE calculation has been compressed or turned negative, usually through years of buybacks and debt. That makes leverage and cash-flow coverage more relevant than book-value multiples. The P/E of 14.8 is therefore the cleaner starting point for valuation, though it needs to be weighed against the company’s commercial-payor exposure and reimbursement risk.

Strategic priorities & outlook

DaVita’s most recent 10-K outlines three operational priorities. The first is to reimagine kidney care so it is more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. The second is to build integrated care capabilities that coordinate treatment across the renal care continuum, from chronic kidney disease through end-stage kidney disease to kidney transplant. The third is to support the Comprehensive Kidney Care Contracting model, with explicit goals of delaying disease progression, promoting home dialysis when appropriate, and incentivizing transplants.

These priorities matter because dialysis is a mature, regulated market where volume growth, payor mix, and government contracting models drive economics. The push toward home dialysis and integrated care is not just clinical positioning; it reflects where CMS policy and reimbursement incentives are heading. The filing also notes that nearly all non-hospital dialysis profits come from commercial payors, so any strategic shift that changes the mix between government and commercial reimbursement can have an outsized effect on the bottom line even when top-line dialysis volume looks stable.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, DaVita’s largest external exposures are regulatory and reimbursement-driven rather than cyclical. The dominant risks are changes to Medicare and Medicaid payment rates from CMS, Medicare Advantage pricing trends, and the design of value-based care programs such as the Comprehensive Kidney Care Contracting model. Drug costs—particularly erythropoiesis-stimulating agents and other dialysis-related pharmaceuticals—also affect margins and can swing with supply agreements or policy changes.

Labor is another macro-level pressure common across care facilities; nursing and clinical staffing shortages show up in wage inflation and retention costs. Trade policy and currency matter less directly than in manufacturing, but dialysis centers rely on imported medical equipment, dialyzers, and related supplies, so tariffs or supply-chain disruptions can raise capital and consumable costs. International operations, while smaller than the U.S. segment, add foreign-exchange and local regulatory exposure across 14 countries. The low beta of 0.87 reflects the relatively recession-resistant demand for dialysis, but that insulation is from the business cycle, not from policy or reimbursement surprises.

Recent developments

The most recent headline flow has been不大 unambiguously negative. On August 15, 2026, defenseworld.net reported that Bank of America Corp DE cut its holdings in DaVita, a notable reduction by a large institutional holder. A day earlier, on August 6, Zacks asked whether DVA is a “great value stock right now,” suggesting the market was already debating whether the valuation had become cheap enough.

The August 5, 2026 Zakh reporting captures the immediate post-Q2 tension: DaVita shares were down in pre-market despite a second-quarter earnings beat, and the downside appeared tied to weaker margins. The same day, Zacks summarized the Q2 earnings call as centered on clinical-led volume growth, which suggests management’s message is about patient volume and quality outcomes rather than margin expansion or pricing power. Taken together, the August news frames DVA as a company posting bottom-line beats that investors are increasingly selling into because margin and mix concerns are outweighing the headline EPS numbers.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten earnings expectations six times, for a 75% beat rate, with an average earnings surprise of 2.3%. The average five-day price move after earnings across those quarters is 6.36% to the upside. Looking only at those summary statistics, one might assume DVA has a reliable post-earnings drift higher. The actual quarter-by-quarter history shows a very different picture: even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise.

The most recent report, filed August 4, 2026, is the clearest example. DaVita delivered EPS of $4.02 against an estimate of $3.88, a 3.6% beat, yet the stock fell 17.24% the next day and 21.78% over the following five trading days. That is the opposite of the textbook “beat and drift.” By contrast, the prior two reports showed enormous positive moves on narrower beats: on May 5, 2026, EPS of $2.87 beat the $2.41 estimate by 19.1%, sending the stock up 23.46% the next day and 27.7% over five days; on February 2, 2026, a 4.9% beat on $3.40 versus $3.24 drove a 21.17% next-day gain and a 23.79% five-day gain. The October 29, 2025 miss, where actual EPS of $2.51 fell 20.8% short of the $3.17 estimate, produced a comparatively modest -6.17% next-day drop and -4.27% over five days.

What this pattern illustrates is that DVA’s post-earnings reaction is not driven by the beat or miss alone. The divergence in outcomes—explosive rallies on some beats and a historic selloff on the most recent beat—suggests the market is repricing the stock based on margin, commercial-payor commentary, guidance, or reimbursement outlook rather than the EPS number itself. For traders and analysts, the lesson is that the unofficial consensus around the next report may matter more than the published estimate. DaVita is scheduled to report again on October 28, 2026, after the close, with a consensus EPS estimate of $3.58.

For a deeper dive into how institutional investors are currently weighing these fundamentals, price action, and forward revisions, readers should consult the full institutional verdict on the platform rather than relying on any single data point.